×
GRAIL Price to Free Cash Flow Ratio 1971-1970 | GRAL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
GRAIL price to free cash flow ratio from 1971 to 1970. Price to free cash flow ratio can be defined as
View More
GRAIL Price to Free Cash Flow Ratio 1971-1970 | GRAL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
GRAIL price to free cash flow ratio from 1971 to 1970. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.6B
Regeneron Pharmaceuticals (REGN)
$127.1B
Vertex Pharmaceuticals (VRTX)
$125.3B
Gilead Sciences (GILD)
$103.1B
Bristol Myers Squibb (BMY)
$99.6B
CSL (CSLLY)
$97.7B
GSK (GSK)
$89.1B
Alnylam Pharmaceuticals (ALNY)
$34.1B
Argenex SE (ARGX)
$32.2B
BioNTech SE (BNTX)
$29.3B
Biogen (BIIB)
$28.5B
Moderna (MRNA)
$26.2B
Illumina (ILMN)
$20.6B
BeiGene (BGNE)
$19.3B
Genmab (GMAB)
$17.8B
BioMarin Pharmaceutical (BMRN)
$16.1B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
Incyte (INCY)
$12.2B
Exact Sciences (EXAS)
$12.1B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.8B
QIAGEN (QGEN)
$10.6B
Legend Biotech (LEGN)
$9.2B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.8B
Intra-Cellular Therapies (ITCI)
$8B
Halozyme Therapeutics (HALO)
$7.9B
Repligen (RGEN)
$7.8B
Exelixis (EXEL)
$7.5B